Iterum Therapeutics Plc (ITRM) Tops Q2 EPS by 2c

Iterum Therapeutics Plc (NASDAQ: ITRM) reported Q2 EPS of ($0.04), $0.02 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Iterum Therapeutics Plc (ITRM) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• Allarity reports Q2 2026 results, completes stenoparib manufacturing